pharma · Multiple Myeloma · Neoplasms
Teva/Actavis Generics
Teva Generics B.V
Teva/Actavis Generics patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Salt Lake City, USA HQ
1992 Founded
100 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Salt Lake City, USA
- Founded
- 1992
- Employees
- 100
- Programs
- 4
- Drugs
- 1
- Patents
- 0
Teva/Actavis Generics patents
0 pharmaceutical patents indexed for Teva/Actavis Generics. 0 expire within 24 months.
Teva/Actavis Generics has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Teva/Actavis Generics have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Teva/Actavis Generics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.